HFrEF Polypill in Sri Lanka RCT

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1672 participants.

Also called NCT07569640

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,672 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07569640
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Sri Lanka (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07569640. Randomized; single masking; primary purpose treatment. Start 2026-08-17 (actual); primary completion 2029-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
HFrEF Polypill in Sri Lanka RCT
Intervention (Other)
Usual Care
Intervention (Drug)
HFrEF Polypill
Lead sponsor
Washington University School of Medicine (class: other)
Collaborator
Centre for Chronic Disease Control, India (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)
Collaborator
RemediumOne (Pvt) Ltd. (class: industry)
Collaborator
University of Kelaniya (class: other)
Collaborator
The George Institute (class: other)

Record details

Record id
cardio:ct-nct07569640
Content hash
57e6b0c4076326a20760536fd3c3933526abeb89cf8af145dbea17a62fc3cf6b